| Sep 3 |
RegenxBio touts positive data for rare disease drug RGX-121
|
| Sep 3 |
REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect
|
| Aug 8 |
REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
|
| Aug 8 |
7 Biotech Stocks to Buy for Their Game-Changing Potential
|
| Aug 6 |
Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder
|
| Aug 6 |
Wall Street Analysts Think Regenxbio (RGNX) Could Surge 234.37%: Read This Before Placing a Bet
|
| Aug 3 |
REGENXBIO Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
| Aug 2 |
REGENXBIO Inc. (RGNX) Q2 2024 Earnings Call Transcript
|
| Aug 1 |
Regenxbio (RGNX) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 1 |
Regenxbio: Q2 Earnings Snapshot
|
